References

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events

10.1056/nejmoa1500858 · 2015 · External reference

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

10.1056/nejmoa1501031 · 2015 · External reference

Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia

10.1016/j.amjcard.2015.02.006 · 2015 · External reference

PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels

10.1016/j.pharmthera.2014.07.004 · 2015 · External reference

Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab

10.1016/j.jacc.2014.07.995 · 2014 · External reference

Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)

10.1161/circulationaha.113.004406 · 2014 · External reference

Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials

2014 · External reference

Lipoprotein(a) metabolism

10.1097/mol.0000000000000070 · 2014 · External reference

Lipoprotein(a) levels in hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation

10.1016/j.jacc.2014.01.063 · 2014 · External reference

Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality

10.1001/jama.2009.1063 · 2009 · External reference

Lipoprotein(a): resurrected by genetics

10.1111/j.1365-2796.2012.02592.x · 2013 · External reference

The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate

10.1172/jci117292 · 1994 · External reference

Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies

10.1016/j.jacc.2012.04.038 · 2012 · External reference

Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor

10.1074/jbc.m114.611988 · 2015 · External reference

Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects

10.1016/j.jacc.2014.02.538 · 2014 · External reference

Effects of extended-release nicotinic acid on apolipoprotein (a) kinetics in hypertriglyceridemic patients

10.1161/atvbaha.115.305835 · 2015 · External reference

Functional characterization and classification of frequent low-density lipoprotein receptor variants

10.1002/humu.22721 · 2015 · External reference

Cellular uptake of lipoprotein[a] by mouse embryonic fibroblasts via the LDL receptor and the LDL receptor-related protein

10.1016/s0022-2275(20)37140-6 · 1997 · External reference

Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro

10.1161/01.atv.19.3.552 · 1999 · External reference

Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia

10.1161/circulationaha.113.004678 · 2013 · External reference

The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans

10.1172/jci117794 · 1995 · External reference

On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects

10.1016/j.atherosclerosis.2014.12.017 · 2015 · External reference

Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis

10.1161/circresaha.113.302655 · 2013 · External reference